2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4174 In vivo CAR T-cell generation and B-cell depletion following UB-VV410 administration in patients with treatment-refractory, active systemic lupus erythematosus (SLE)/lupus nephritis (LN)

Huijuan Mao, PhD, Laurie Beitz, MD2, Christine Dehner3, Jeffrey Teoh, PhD4, Luke Walker, MD5, Jie Chen, MD6
1 Jiangsu Provincial Hospital, Nanjing, China
2 Umoja Biopharma, Seattle, Washington, United States
3 Umoja Biopharma, Seattle, Washington, United States
4 Umoja Biopharma, Seattle, Washington, United States
5 Umoja Biopharma, Seattle, Washington, United States
6 IASO Biotherapeutics, Nanjing, China

Standard treatment for autoimmune diseases (AID) typically involves chronic immunosuppression. B cells play a central role in the pathogenesis of AID, such as SLE, through secretion of autoreactive antibodies. Eradicating B cells may thus prove an effective strategy in SLE treatment. Autologous, ex vivo-manufactured chimeric antigen receptor (CAR) T cells targeting the B-cell antigen CD19 have shown therapeutic benefit in hematologic malignancies and, more recently, activity in various AID by inducing B-cell depletion and reconstitution with a naive B-cell repertoire, termed immune reset. CD22 represents a promising potential target for CAR T cells in AID as its expression is also limited to B?cells.   

UB-VV410 is an investigational product that generates anti-CD22 CAR T cells in vivo without need for apheresis or lymphodepletion. Study UB-VV410CI002 (NCT07109986) is a Phase 1, open-label, dose-finding study of UB-VV410 in active, treatment-refractory SLE/LN (class III or IV) following treatment with ≥?2 prior immunosuppressive regimens (eg, alkylators, anti-metabolites, calcineurin inhibitors, monoclonal antibodies) of ≥ 12 weeks’ duration. Eligible subjects receive a single intravenous (IV) dose of UB-VV410. Primary endpoints include safety/tolerability of UB-VV410; secondary endpoints measure preliminary SLE/LN clinical activity (SLE Responder Index 4 [SRI-4], BILAG A and B, and Lupus Low Disease Activity State [LLDAS]). Exploratory endpoints include anti-CD22 CAR T-cell generation, expansion kinetics, and on-target activity measured by B-cell depletion kinetics.  

To date, 3 subjects (2 Class IV LN and 1 Class IV + V LN) have been treated with UB-VV410 at Dose Level 1 (DL1). CAR T cells were generated in all 3 subjects and peaked at Days 10 to 21. Onset of profound B-cell depletion occurred in association with peak CAR T-cell levels in the peripheral blood in all subjects and has been sustained throughout the present study period. All 3 subjects have demonstrated improvement in proteinuria that is sustained through 180 days, as assessed by 24-hour protein excretion and urine protein-creatinine ratio (uPCR).   

UB-VV410 was well tolerated in the first 2?subjects treated, with no dose-limiting toxicities (DLTs) reported. Both subjects had normal baseline serum complements, and one subject had a minimally elevated dsDNA autoantibody level. While being maintained on 15 mg qd prednisone as background therapy, the third subject experienced a flare of underlying active lupus/renal disease (as evidenced by low serum complement and significantly elevated dsDNA autoantibody level) following a 3-week period of immunosuppressant (mycophenolate mofetil) washout and subsequent UB-VV410 administration. In the setting of the disease flare, the subject experienced 2?DLTs (Grade?4 acute cardiac insufficiency and Grade 3 peritonitis) and deterioration of renal function. These clinical events resolved after anti-CD22 CAR T-cell expansion and onset of complete B-cell depletion in concert with initiation of additional SLE therapies. The subject is being followed for safety/efficacy assessments. The study protocol was revised to shorten the washout period for prior immunosuppressive therapy to minimize disease flare risk. Enrollment continues at DL1.   

In summary, CAR T-cell expansion and profound durable B-cell depletion have been demonstrated for 3 subjects treated with UB-VV410. All 3 subjects show evidence of sustained improvement of disease activity in the form of decreased proteinuria at 6 months. Additional long-term follow-up of translational and clinical parameters for treated subjects will be available at the time of presentation.      

Huijuan Mao, PhD: No relevant conflicts of interest to declare.